We are dedicated to providing a new dawn or "eos" for patients with mental health conditions by developing next generation, first- and best-in-class therapies. Over 100 million patients in the United States are affected by neuropsychiatric disorders, with anxiety and substance use disorders among the largest areas of unmet medical need. Our clinical-stage pipeline was licensed from Roche and includes oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5 with broad potential in general anxiety, social anxiety, substance use disorders and cognitive impairment. Newleos was co-founded by Longwood Fund, Federico Bolognani, M.D., Ph.D., and William Martin, Ph.D., seasoned experts in company creation and CNS drug development.

Biotechnology

Health Care

Life Sciences

Psychology

Therapeutics

Newleos Therapeutics

David Donabedian

Hector Guzman

Chris Jepsen

Brian Shea

Newleos Therapeutics

Org chart

Teams

Offices